<DOC>
	<DOCNO>NCT02220803</DOCNO>
	<brief_summary>This short term open , randomize cross trial explore compare efficacy pharmacological carbonic anhydrase ( CA ) inhibition obstructive sleep apnea ( OSA ) relate hypertension . Patients randomize receive Acetazolamide ( Diamox® ) ( ACZ ) , Continuous Positive Airway Pressure ( CPAP ) CPAP plus ACZ 2 week . Following 2 week wash-out period study participant receive alternative treatment regimen . The total length study 10 week . The effect carbonic anhydrase inhibition blood pressure , hemodynamics sleep apnea investigate . Study hypothesis : Carbonic anhydrase inhibition alone combination nCPAP prominently reduce blood pressure patient OSA . Further hypothesize CA inhibition induce direct pharmacological effect vascular stiffness evidence overnight non-invasive assessment vascular stiffness effect particularly strong patient also respond reduction blood pressure .</brief_summary>
	<brief_title>A Short Term Open , Randomized Cross-over Trial Exploring Effect Carbonic Anhydrase Inhibition Acetazolamide Sleep Apnea Associated Hypertension Vascular Dysfunction</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Sleep Apnea , Obstructive</mesh_term>
	<mesh_term>Acetazolamide</mesh_term>
	<criteria>Provision inform consent prior study specific procedure Males 18 75 year An ApneaHypopnea Index ( AHI ) &gt; 15 Epworth Sleepiness Scale score ( ESS ) &gt; 6 verified PSG recording . Patients establish hypertension ( systolic/diastolic blood pressure &gt; = 160/95 , either systolic diastolic account ) . Clinically normal physical finding laboratory value , judge investigator Body mass index &gt; = 35 kg/m2 Hypersensitivity sulfonamides acetazolamide Patients ongoing medication sulphonamides patient specific antihypertensive treatment . History severe allergy/hypersensitivity ongoing allergy/hypersensitivity . Subjects seizure disorder Patients clinically verified central sleep apnea Clinically significant renal ( serum creatinine &gt; 2.0 mg/dL &gt; 130 micromol/L ) , neurological , metabolic ( e.g . Type 1 2 diabetes ) , haematological hepatic disease ( ASAT ALAT &gt; 2 time upper limit normal ) . Subjects occupational risk potentially exaggerated daytime sleepiness handle complex machinery professional driving Unstable angina pectoris , unstable hypertension ( poorly control diabetes ( HbA1C &lt; 52 mmoles/mol , fast plasma glucose &gt; 7 mmoles/l ) . Clinically significant congestive heart failure . Myocardial infarction coronary vessel intervention within previous 6 month period . Subjects uncontrolled hypertension ( define diastolic blood pressure ≥110 mmHg and/or systolic blood pressure ≥180 mmHg without medication ) . Previously diagnose treat clinically significant cardiac arrhythmia Clinically significant chronic pulmonary gastrointestinal disease . Clinical history depression judge investigator previous present clinically significant psychiatric disease Suspected confirm poor compliance Alcohol drug abuse last year . Subjects significant condition , opinion investigator , could interfere participation study . Severe nocturnal hypoxia define 10 episode oxygen desaturation exceed 50 % sign lack resaturation desaturations previous recording accord investigator judgment Participation another clinical study last 6 month . Inability understand complete questionnaire .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Acetazolamide</keyword>
	<keyword>Zonegran</keyword>
	<keyword>Obstructive Sleep apnea</keyword>
	<keyword>Apnea</keyword>
	<keyword>Respiration Disorders</keyword>
	<keyword>Sleep Disorders</keyword>
	<keyword>Cardiovascular</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Carbonic Anhydrase</keyword>
	<keyword>Carbonic Anhydrase Inhibitors</keyword>
	<keyword>Enzyme Inhibitors</keyword>
	<keyword>Sulfonamides</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Vascular stifness</keyword>
</DOC>